A detailed history of Parkwood LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Parkwood LLC holds 11,390 shares of JANX stock, worth $619,502. This represents 0.06% of its overall portfolio holdings.

Number of Shares
11,390
Holding current value
$619,502
% of portfolio
0.06%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $400,016 - $737,844
11,390 New
11,390 $477,000
Q4 2022

Feb 14, 2023

SELL
$11.1 - $18.26 $131,901 - $216,983
-11,883 Reduced 35.63%
21,469 $283,000
Q3 2022

Nov 14, 2022

SELL
$10.82 - $16.84 $4,306 - $6,702
-398 Reduced 1.18%
33,352 $452,000
Q2 2022

Aug 15, 2022

BUY
$9.52 - $15.65 $52,283 - $85,949
5,492 Added 19.44%
33,750 $34,000
Q1 2022

May 13, 2022

SELL
$13.24 - $20.24 $51,238 - $78,328
-3,870 Reduced 12.05%
28,258 $405,000
Q4 2021

Feb 11, 2022

BUY
$15.44 - $27.32 $175,259 - $310,109
11,351 Added 54.63%
32,128 $634,000
Q3 2021

Nov 12, 2021

BUY
$20.7 - $34.69 $430,083 - $720,754
20,777 New
20,777 $449,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.27B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Parkwood LLC Portfolio

Follow Parkwood LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkwood LLC with notifications on news.